Most stimulant-free pump ingredients work through a single pathway: nitric oxide production. Citrulline, arginine, and nitrates all lean on it.
VasoDrive-AP® doesn't.
Peptides are having a moment in sports nutrition. VasoDrive-AP® didn't arrive with the wave. It's been a clinically studied cardiovascular ingredient for 30 years, and a new 2026 study finally tests it for muscle pump in lifters.
It's a peptide (specifically a pair of milk-derived tripeptides) with a cardiovascular research base stretching back three decades, long before "peptide" became shorthand for innovation in sports nutrition. Now, with the first published study connecting it directly to muscle pump in resistance-trained lifters, VasoDrive-AP® has another reason to move from a cardiovascular health ingredient into the pre-workout conversation.
Also sold as AmealPeptide® outside of sports nutrition, VasoDrive-AP® is manufactured by Asahi Group Foods and distributed in the US by Maypro Industries. It's made from two lactotripeptides derived from milk casein: Valyl-Prolyl-Proline (VPP) and Isoleucyl-Prolyl-Proline (IPP). Together, they carry more than 50 published studies, an unusually deep research base for a single branded ingredient, and one built almost entirely before the current peptide boom in sports nutrition even started.
VasoDrive-AP®: The Original Pump Peptide
Peptides are having a moment in this industry right now, showing up in everything from muscle-building capsules to recovery stacks. VasoDrive-AP® didn't arrive with that wave. It was already a clinically-studied cardiovascular ingredient years before "peptide" became a label buzzword, and it continues to support a category that's finally catching up to what it's always been.
A few reasons this one deserves a longer look:
- It works through two distinct vasodilation pathways instead of one: nitric oxide support and ACE inhibition
- It's backed by more than a dozen double-blind, placebo-controlled human trials on blood pressure and arterial health
- A brand-new 2026 study is the first to test it specifically for muscle pump and hypertrophy in resistance-trained men
- It already shows up in pre-workout and testosterone-support products from multiple brands
We'll dig into the mechanisms, the clinical evidence, and that new pump study in detail below. First, if you want to stay on top of new VasoDrive-AP® research and product launches from Maypro, sign up for our alerts:
Subscribe to PricePlow's Newsletter and Alerts on These Topics
Let's start with where these peptides actually came from.
What Are Lactotripeptides? VPP and IPP Explained
VPP and IPP didn't start in a sports nutrition lab. They were discovered in Japan in the 1990s, in fermented dairy research built around Calpis, a sour milk drink cultured with Lactobacillus helveticus and yeast.
A Discovery Rooted in Fermented Milk
Researchers noticed that ACE-inhibitory activity in the milk rose during fermentation, and when they purified the compounds responsible using four-step HPLC, they identified two tripeptides: Val-Pro-Pro and Ile-Pro-Pro.[1] That original research came out of the same company lineage (Calpis, later folded into Asahi Group Foods) that continues to publish lactotripeptide research today, including the 2026 pump study we'll get to below.
From Casein to Standardized Peptide
VPP is released from beta-casein. IPP comes from both beta- and kappa-casein. Both require a specific enzymatic step to free them from the surrounding protein without breaking them down further, which is exactly what VasoDrive-AP®'s manufacturing process is built to do.
The material is produced in New Zealand by Asahi Group Foods, the same company lineage behind the original 1990s discovery research, by hydrolyzing casein with a protease derived from Aspergillus oryzae, the same mold used in traditional Japanese fermentation like miso and sake, in a controlled process that releases VPP and IPP intact rather than breaking them all the way down to free amino acids. Maypro Industries then distributes and markets the finished ingredient in the US under the VasoDrive-AP® name.
Note that this is a much different process from simply drinking fermented milk. Ordinary dairy products contain VPP and IPP in trace amounts at best, nowhere close to the concentrations used in the clinical research behind this ingredient, which is the entire reason a standardized, concentrated form exists in the first place.
-
Built to Survive Digestion
The intact structure matters for one major reason: most dietary peptides get destroyed in digestion before they can do anything.
VPP and IPP, however, are built differently. Their proline-rich structure resists the digestive enzymes that would normally chew up a tripeptide, and human research confirms this actually holds up in the body. In a crossover study measuring plasma levels after a lactotripeptide-enriched drink, IPP showed a 2.1-fold higher blood level compared to placebo, confirming the peptide survives digestion and enters circulation intact rather than getting broken down into its individual amino acids first. Peak plasma concentration was also meaningfully higher after the active drink than after placebo.[2]
That's the entire premise behind why a peptide this small can have a measurable cardiovascular effect at all, and it's a detail that separates VPP and IPP from a lot of other bioactive peptides that never make it past the gut intact.
-
The ACE Connection: A First Look
Why does any of this matter for blood flow? VPP and IPP are both mild inhibitors of angiotensin-converting enzyme (ACE), the same enzyme targeted by an entire class of blood pressure medications. ACE normally does two things:
- It converts angiotensin I into angiotensin II (a potent vasoconstrictor), and
- It breaks down bradykinin (a vasodilator).
Overview of VasoDrive-AP®, showing the 508mg daily dose, its pump and recovery benefits, and the standardized VPP and IPP content.
Block ACE, even partially, and you tip the balance toward relaxed, dilated blood vessels rather than constricted ones.[3] That single mechanism is the foundation for everything else in this article, and it's a mechanism most pump ingredients on the market (like citrulline and arginine) simply don't have.
VasoDrive-AP® and AmealPeptide®: One Peptide, Two Names
Here's something that trips up a lot of label readers: VasoDrive-AP® and AmealPeptide® are the same underlying ingredient, made the same way, produced in New Zealand by Asahi Group Foods. The difference is licensing and distribution. VasoDrive-AP® is the name Maypro Industries uses to distribute the ingredient for sports nutrition and food applications, while AmealPeptide® is the name used in the broader health and nutraceutical marketplace.
Same casein hydrolysate, same VPP and IPP content, different brand name depending on where it's sold. But the research for either one does translate to the others.
-
Cracking the 254mg vs. 508mg Dosing Code
That naming split explains a dosing question that trips up a lot of readers, too: some labels list VasoDrive-AP® at 254mg, others at 508mg, and AmealPeptide® is generally licensed for use at 508mg specifically. These aren't different strengths of the same material, though. VasoDrive-AP® is standardized to provide a minimum of 6.7mg of combined VPP and IPP per gram of material. Run the math and 254mg works out to roughly 1.7mg of combined tripeptides, while 508mg works out to roughly 3.4mg. Those are the exact low-dose and high-dose amounts used in the new 2026 pump study covered below, and the same 3.4mg figure shows up directly on current third-party labels using the 508mg dose, which lists it as "508mg VasoDrive-AP®... providing 3.4mg Lactotripeptides."
In practice, 254mg is the lighter, more accessible dose you'll see in some pre-workout stacks, and 508mg is the full clinical dose most closely matching the bulk of the research below, used in the most formidable of products or seen when stacking two products together that are each dosed at 254mg.
That standardization is also the biggest practical difference between VasoDrive-AP® and the generic "sour milk" or "fermented milk drink" products used in a lot of the older Japanese research. Those studies worked with fermented milk beverages where VPP and IPP content could vary from batch to batch. A standardized, guaranteed-minimum casein hydrolysate removes that variability, which matters if you're trying to formulate a product to a specific, repeatable dose.
-
Where VasoDrive-AP® Fits in the Pump Category
VasoDrive-AP® clinical benefits page, built around a chart where forearm blood flow rose after one week of lactotripeptides while placebo stayed flat.
It's also worth placing VasoDrive-AP® next to the rest of the pump category here. Citrulline, arginine, and nitrate-based ingredients dominate stimulant-free pre-workouts, and all of them work by supporting nitric oxide production. None of them carry documented ACE-inhibitory activity, the mechanism behind an entire class of blood pressure medications. That's the real differentiator covered in the next section, and it's the reason VasoDrive-AP® doesn't directly compete with those ingredients so much as complement them.
How VasoDrive-AP® Works: Two Mechanisms of Vasodilation
Most nitric oxide boosters, citrulline and arginine included, work through one pathway. VasoDrive-AP® works through two, and that combination is what separates it from the rest of the pump category.
-
Mechanism One: ACE Inhibition
ACE inhibition is the first and best-documented mechanism. ACE is part of the renin-angiotensin-aldosterone system, the body's primary blood pressure regulation pathway. By partially blocking ACE, VPP and IPP reduce the formation of angiotensin II (a potent vasoconstrictor) while preserving bradykinin, a vasodilating peptide that ACE would otherwise break down.[3]
In isolated rat arteries, IPP directly enhanced bradykinin-induced and angiotensin-(1-7)-induced vessel relaxation, an effect that held up even in older vessels with reduced baseline function.[4] A follow-up study digging into the receptor biology found the same pattern: IPP improved bradykinin-induced vasodilation in an age-dependent way, with the effect largely running through the mas-receptor pathway rather than the classical bradykinin receptors alone, suggesting IPP's benefit may be most pronounced in vessels that have already lost some of their natural elasticity.[5]
-
Mechanism Two: eNOS and Nitric Oxide Support
eNOS and nitric oxide support is the second mechanism, and the one most closely tied to VasoDrive-AP®'s "arterial flexibility" claim. In spontaneously hypertensive rats, five days of VPP and IPP administration significantly upregulated the gene for endothelial nitric oxide synthase (eNOS) in aortic tissue by 1.89-fold. The same experiment found an even larger 2.81-fold increase in connexin 40, a gap-junction protein that helps coordinate signaling between adjacent endothelial cells along a blood vessel wall.[6]
It's worth being precise about what that study actually showed: it's gene expression data from an animal model, not a direct measurement of nitric oxide output in humans. The human evidence for this pathway is more indirect, but it points in the same direction: In men with mild hypertension, a week of casein hydrolysate intake significantly increased reactive hyperemia (blood flow following a period of induced occlusion), a functional marker of endothelial and nitric oxide-driven vasodilation, independent of any change in blood pressure itself.[7]
That last point matters: the endothelial improvement showed up even though blood pressure itself didn't move much, which is a good sign that VPP and IPP are doing something to the vessel wall directly rather than just following a blood pressure change.
-
Two Mechanisms, One Outcome
Combined, ACE inhibition and eNOS support give VasoDrive-AP® two independent routes to the same outcome: more relaxed, more responsive blood vessels. That's also the mechanistic argument for stacking it with a citrulline or nitrate-based pump ingredient rather than swapping one for the other, since they aren't competing for the same pathway.
Clinical Evidence: Blood Pressure and Arterial Health
The bulk of VasoDrive-AP®'s research sits in blood pressure and arterial stiffness, and it's deep enough to support two separate meta-analyses along with dozens of individual randomized trials behind them.
-
What the Meta-Analyses Show
The larger meta-analysis pooled 18 studies and 1,194 Japanese subjects, finding a significant systolic blood pressure reduction of 5.63mmHg compared to placebo, with a larger effect in subjects who were already hypertensive (-8.35mmHg) than in non-hypertensive subjects (-3.42mmHg). Even at typical daily intakes under 5mg, the effect held at -6.01mmHg overall.[8]
A CALPIS poster reporting lower exercise heart rate and reduced muscle-damage markers in older men taking VPP and IPP versus placebo.
A broader meta-analysis covering both Japanese and European trials found a smaller pooled effect of -2.95mmHg systolic and -1.51mmHg diastolic, noting that the Japanese studies showed larger reductions than the European ones.[9] An earlier meta-analysis of 12 trials found a similar pattern at -4.8mmHg systolic and -2.2mmHg diastolic.[10]
Individual dose-response work backs this up directly. One placebo-controlled trial tested four doses (0, 1.8mg, 2.5mg, and 3.6mg of combined VPP and IPP) and found a clean dose-dependent drop in systolic blood pressure across all three active doses.[11] A separate crossover trial in 70 subjects with prehypertension or stage 1 hypertension found that an IPP-only capsule (7.5mg per dose) significantly lowered systolic blood pressure by 3.8mmHg and diastolic by 2.3mmHg in the stage 1 hypertensive subgroup specifically, with no significant effect in the milder prehypertensive group. That trial also directly measured plasma renin activity and angiotensin levels and found no significant change, suggesting the blood pressure benefit isn't purely explained by classic ACE inhibition alone.[12]
-
Beyond Blood Pressure: Arterial Stiffness
Several trials measured arterial stiffness directly, which is the marker most closely tied to VasoDrive-AP®'s "arterial elasticity" positioning. In 89 hypertensive subjects given a dose-escalation protocol (5mg per day for 12 weeks, then 50mg per day for 12 more), augmentation index (a pulse-wave measure of arterial stiffness) and endothelial function both improved.[13]
In Japanese subjects with stage-1 hypertension, 8 weeks of VPP and IPP significantly reduced brachial-ankle pulse wave velocity (a standard arterial stiffness marker) by 73.9cm/s compared to just 8.4cm/s with placebo, alongside a central systolic blood pressure reduction of 11.0mmHg versus 4.5mmHg.[14]
Two separate trials from the same research group found consistent pulse wave velocity improvements in participants with high-normal blood pressure and metabolic syndrome, alongside improvements in cardiac output-related markers like stroke volume.[15][16]
-
A Bonus Benefit: Cerebral Blood Flow
A Kyoto Prefectural University poster showing milk casein peptides eased next-day soreness and fatigue in older men after downhill treadmill walking.
The vascular benefits extend beyond the arteries you can measure at the arm, too. An 8-week trial in middle-aged and older adults found a significant increase in middle cerebral artery blood flow velocity with lactotripeptide intake,[17] and a related trial linked lactotripeptide intake to improved cerebral oxygenation during a cognitive task, with the degree of improvement correlating to gains in arterial stiffness.[18] Neither of those trials was designed for a pre-workout audience, but they're a useful reminder that the vasodilation story here extends well past the muscles you're training.
VasoDrive-AP® for Pre-Workout Pumps and Performance
This is where VasoDrive-AP®'s story gets a new chapter. Almost all of the research above was built around blood pressure and general vascular health, not training. That changed in January 2026.
-
The First Pump-Specific Study: Ohigashi et al. 2026
A team of Japanese researchers set out to answer a question nobody had directly tested before: does lactotripeptide intake actually improve muscle pump during resistance training?
Thirty-six resistance-trained men (with at least three months of leg training history) were split into placebo, low-dose (0.7mg VPP plus 1.0mg IPP daily, matching the 254mg VasoDrive-AP® dose), or high-dose (1.4mg VPP plus 2.0mg IPP daily, matching the 508mg dose) groups for four weeks of daily supplementation alongside their normal training. Muscle pump was measured two ways: objectively, using thigh circumference before and immediately after a standardized cycle ergometer test, and subjectively, using a five-point questionnaire completed right after each session.[19]
The results split in an interesting way by dose. In the low-dose group, subjective ratings of post-exercise muscle pump significantly improved compared to placebo. In the high-dose group, the subjective pump ratings didn't reach significance, but the objective measurements did: pre-exercise thigh circumference and lean body mass both increased significantly over the 4 weeks, and the increase in thigh circumference immediately after training was significantly greater than placebo.
Across the full group regardless of dose, the subjective pump score and the objective thigh circumference change were significantly correlated, meaning the people who felt a bigger pump also measured a bigger one. High-dose intake also significantly reduced post-training fatigue scores and improved training motivation the morning after a workout, and it reduced LDL cholesterol along the way. In the subgroup of participants who started with below-average flow-mediated dilation (a vascular marker tied directly to the eNOS pathway discussed above), the high-dose group showed a meaningful upward trend in that marker after 4 weeks, and the size of that vascular improvement directly correlated with the size of the muscle pump response.[19]
Although both groups saw a reduction in blood pressure, only the VasoDrive-AP group's reduction achieved statistical significance.[20]
This is evidence the sports industry needed for pump, muscle size, recovery, and motivation. Note that it's one exploratory trial with 34 completing participants (12 placebo, 10 low-dose, 12 high-dose), and the authors themselves call for larger, confirmatory studies with tighter control over training volume and protein intake before drawing firm conclusions. It's an exciting first result for an audience that cares about training, but not a finished case. It's the kind of study that ages well: replicate it a few more times with bigger samples, and this becomes one of the most relevant pieces of pump research in the category.
-
Recovery, Fatigue, and Training Motivation
The pump study isn't the only place VasoDrive-AP®'s tripeptides intersect with training. In 18 young, healthy men performing resistance exercise (leg press and bench press at 70 to 100% of 12-rep max), fermented milk supplementation significantly suppressed next-day muscle soreness compared to placebo (a soreness score of 12.6 versus 14.2) and blunted the exercise-induced drop in respiratory quotient, a marker of substrate metabolism, without a matching change in the placebo group.[21]
In a separate trial, 22 young men performing high-intensity eccentric exercise (a reliable way to induce muscle damage) saw less of a drop in maximal isometric force after taking lactotripeptides, and the group's brachial artery diameter significantly increased in a way that tracked directly with the force preservation, tying the recovery benefit back to the same vasodilation mechanism covered above.[22] A third study in young men performing acute resistance exercise found that lactotripeptide intake attenuated the post-exercise spike in both arterial stiffness and systolic blood pressure that showed up in the placebo group, an effect that lasted through the first hour after training.[23]
The recovery story extends into older, less trained populations as well. In middle-aged to elderly men performing downhill walking, a reliable model for inducing delayed muscle soreness, lactotripeptide intake significantly reduced next-day muscle soreness and same-day fatigue ratings compared to placebo.[24] It's a different training context than a gym-based lifter, but the underlying mechanism, better blood flow and reduced vascular strain around exercise-induced muscle damage, is the same one driving the resistance-training results above.
Safety, Tolerability, and Regulatory Status
A very thorough meta-analysis of lactotripeptides found in VasoDrive-AP (VPP / Valine-Proline-Proline and IPP / Isoleucine-Proline-Proline) shows consistently significant reduction in blood pressure, both systolic and diastolic.[25]
VasoDrive-AP® has one of the cleaner safety profiles in the ACE-inhibitor-adjacent ingredient space, largely because it's a mild, food-derived inhibitor rather than a pharmaceutical dose. Dry cough, the hallmark side effect of prescription ACE inhibitors, has been specifically looked for and not found across multiple trials.[26][27]
A 144-person, 12-week trial reported no side effects at all alongside its blood pressure findings, with no meaningful changes in blood or urine markers in either group.[28]
-
Stress-Testing Excess Intake
Researchers have also specifically stress-tested excess intake, which is a useful safety signal for an ingredient increasingly used in stacked formulas alongside other pump ingredients. A trial giving subjects five times the effective dose for four weeks found a mild blood-pressure-lowering effect in subjects with elevated blood pressure, no effect in normotensive subjects, and no clinically important adverse events.[29]
An even larger excess-intake trial, 14 tablets (28g) daily for a week in healthy volunteers, found no marked changes in blood pressure, pulse rate, or blood chemistry, and no dry cough, though some temporary and self-resolving gastrointestinal symptoms were noted.[30] A separate two-week excess-intake study in 43 healthy volunteers reported the same overall result: no adverse effects, including no gastrointestinal issues, at 6 tablets (12g) daily.[31]
-
Regulatory Status: GRAS and FOSHU
On the regulatory side, VasoDrive-AP® is self-affirmed Generally Recognized As Safe (GRAS) for use in foods and dietary supplements in the US. That means Asahi's/Maypro's own safety determinations support that status. Separately, the ingredient is recognized under Japan's FOSHU (Foods for Specified Health Uses) system, a government-reviewed functional food category.
Because it's derived from milk casein, anyone with a milk protein allergy should treat it like any other dairy-derived ingredient, even though Maypro reports lactose content below the detectable threshold (under 0.05%), which is a separate issue from casein protein allergenicity.
Applications and Dosing: How Much Do You Need
MuscleTech Test Peptide T10 combines VasoDrive-AP and TestFACTOR to support testosterone levels, blood flow, and training performance. Full clinical doses of both ingredients in just 2 capsules daily.
The published dose range for VPP and IPP is wide, and it's worth separating "material dose" from "active tripeptide dose" before you compare studies. Clinical effects on blood pressure have been shown at combined VPP and IPP intakes as low as 1.8mg per day,[11] with most of the supporting literature clustering in the 2.6mg to 10.5mg per day range, and dose-escalation studies going as high as 50mg per day.[13]
For VasoDrive-AP® specifically, that translates to two commonly used material doses: 254mg (about 1.7mg combined tripeptides) and 508mg (about 3.4mg combined tripeptides, the dose most closely matching the bulk of the clinical evidence and the high-dose arm of the 2026 pump study).
Timing varies by goal. The pump study had participants take their dose before training, while most of the blood pressure research uses once or twice daily dosing independent of exercise timing. Across both situations, effects tend to build in over three to four weeks of consistent daily intake rather than showing up acutely, which is worth setting expectations around: this isn't an ingredient where you'll feel something different in a single pre-workout session the way you might with caffeine.
Format and Stacking Options
Format-wise, VasoDrive-AP® shows up as a standardized powder that formulators can drop into capsules, tablets, or powdered pre-workout blends.
Because VasoDrive-AP® works through ACE inhibition rather than the nitric oxide pathway alone, it stacks logically alongside citrulline, arginine, or nitrate-based ingredients rather than competing with them, since a formula built on both mechanisms is covering more ground than one relying on nitric oxide alone.
It also pairs well within Maypro's own ingredient lineup: Oligonol®, a lychee-derived polyphenol studied for endurance and circulation, and PurpleForce®, an AMPK-activating purple tea extract, both hit adjacent pathways worth considering in the same formula, whether the goal is a broader cardiovascular angle or a more complete pump and endurance stack.
Sports Nutrition Supplements Containing VasoDrive-AP®
There are several popular supplements using VasoDrive-AP®, many of which have been covered on this blog in the past:
-
CORE Nutritionals PUMP Fun Sweets Cotton Candy
CORE Nutritionals uses VasoDrive-AP® in its stimulant-free PUMP formula, where it replaced a mushroom-based ingredient in the Fun Sweets Core PUMP flavor collaboration. Stacked with CORE FURY, the combined dose reaches the full 508mg clinical amount. If you want to see the ingredient built into a flavor designed specifically around it (yes, cotton candy), it's worth a look, and it's the product that first got PricePlow digging into VasoDrive-AP®'s dosing math.
Core Nutritionals PUMP – Deals and Price Drop Alerts
Get Price Alerts
No spam, no scams.
Disclosure: PricePlow relies on pricing from stores with which we have a business relationship. We work hard to keep pricing current, but you may find a better offer.
Posts are sponsored in part by the retailers and/or brands listed on this page.
-
MuscleTech Test Peptide T10
Launched in 2026, MuscleTech's Test Peptide T10 capsule pairs VasoDrive-AP® at its full 508mg dose with TestFACTOR® at 325mg, aiming at testosterone support and libido rather than a pre-workout pump specifically. Two capsules deliver both ingredients at their studied amounts, no proprietary blends involved. It's a good example of VasoDrive-AP® moving into new product categories outside the shaker bottle, and part of MuscleTech's broader move toward single-purpose, peptide-branded daily supplements.
MuscleTech Test Peptide T10 – Deals and Price Drop Alerts
Get Price Alerts
No spam, no scams.
Disclosure: PricePlow relies on pricing from stores with which we have a business relationship. We work hard to keep pricing current, but you may find a better offer.
Posts are sponsored in part by the retailers and/or brands listed on this page.
-
Morphogen Nutrition VOLUGEN
Morphogen's stimulant-free pump and performance formula includes VasoDrive-AP® at 508mg alongside citrulline and other vasodilation-focused ingredients, positioned as a stackable option alongside the brand's stimulant-based ALPHAGEN for lifters who want pump support without added caffeine. You can read about it in the most recent Volugen / Alphagen article update.
Morphogen Nutrition VoluGEN – Deals and Price Drop Alerts
Get Price Alerts
No spam, no scams.
Disclosure: PricePlow relies on pricing from stores with which we have a business relationship. We work hard to keep pricing current, but you may find a better offer.
Posts are sponsored in part by the retailers and/or brands listed on this page.
The Bottom Line on VasoDrive-AP®
Morphogen Nutrition just dropped major upgrades to ALPHAGEN and VOLUGEN pre-workouts. That 10g L-tyrosine dose is back, plus some serious formula improvements that caught our attention. These work solo or stacked for maximum flexibility.
VasoDrive-AP® isn't a new ingredient. It's a peptide with three decades of cardiovascular research behind it, built on a mechanism (ACE inhibition alongside eNOS support) that almost nothing else in the pump category can claim. What's new is the research (and hype) finally catching up to where the ingredient has already been showing up: pre-workouts, testosterone-support capsules, and performance formulas across the industry.
The 2026 pump study is a first step, not a final word. It's a great exploratory trial, and the researchers behind it are already calling for larger studies to confirm what they found. But it gives lifters and formulators a legitimate, peer-reviewed reason to look at this peptide as more than a blood pressure ingredient, something the decades of cardiovascular data alone couldn't do for a pre-workout audience.
With peptides now one of the fastest-growing categories in sports nutrition, VasoDrive-AP® has an unusual story to tell: an ingredient that predates the trend by decades, backed by the kind of clinical depth most newer peptides haven't built yet, and only now getting its first look at the exact audience it may have been helping all along.
Comments and Discussion (Powered by the PricePlow Forum)